Literature DB >> 17143821

Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Paul G Ambrose1, Sujata M Bhavnani, Christopher M Rubino, Arnold Louie, Tawanda Gumbo, Alan Forrest, George L Drusano.   

Abstract

Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of antimicrobial agents for the treatment of experimentally induced infection. Today, animal pharmacokinetic-pharmacodynamic (PK-PD) infection models serve as a cornerstone of the preclinical assessment process for antibacterial agents and dose and dosing interval selection, as decision support for setting in vitro susceptibility breakpoints, and, finally, for the evaluation of the meaning of in vitro resistance. Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143821     DOI: 10.1086/510079

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  240 in total

1.  Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.

Authors:  Christopher M Rubino; Alan Forrest; Sujata M Bhavnani; Gary Dukart; Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

3.  Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Scott A Van Wart; Christopher M Rubino; Daniel K Reynolds; Alan Forrest; George L Drusano; Tatiana Khariton; H David Friedland; Todd A Riccobene; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

4.  In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.

Authors:  Dora E Wiskirchen; Jared L Crandon; Guilherme H Furtado; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

5.  Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.

Authors:  Paul G Ambrose; Jeffrey P Hammel; Sujata M Bhavnani; Christopher M Rubino; Evelyn J Ellis-Grosse; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

6.  Does prolonged infusion allow lower daily dose of meropenem than bolus dosing?

Authors:  Eric Poulin; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

7.  Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

Authors:  Jocelyn Y Ang; Nahed Abdel-Haq; Frank Zhu; Abrar K Thabit; David P Nicolau; Michael J Satlin; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Authors:  Valérie Zeller; Frédérick Durand; Marie-Dominique Kitzis; Luc Lhotellier; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.

Authors:  Robyn Defife; Marc H Scheetz; Joe M Feinglass; Michael J Postelnick; Kimberly K Scarsi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.